No Data
HPGC Renmintongtai Pharmaceutical Flags 21 Million Yuan Reduction in 2024 Profit
2024 ANNUAL REPORT
2024 Annual Report Summary
HPGC Renmintongtai Pharmaceutical Corporation (600829.SH): Net income for 2024 is 0.213 billion yuan, a decrease of 27.00% year-on-year.
Gelonghui reported on April 11 that HPGC Renmintongtai Pharmaceutical Corporation (600829.SH) announced its 2024 annual report, with revenue of 10.048 billion yuan during the reporting period, a year-on-year decrease of 3.29%; net income attributable to shareholders of the listed company was 0.213 billion yuan, a year-on-year decrease of 27.00%; basic EPS was 0.3678 yuan.
HPGC Renmintongtai Pharmaceutical (SHSE:600829) Is Reinvesting At Lower Rates Of Return
Optimism for HPGC Renmintongtai Pharmaceutical (SHSE:600829) Has Grown This Past Week, Despite One-year Decline in Earnings
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
